Cargando…

Oxidative profile exhibited by Mucopolysaccharidosis type IVA patients at diagnosis: Increased keratan urinary levels

Morquio A disease (Mucopolysaccharidosis type IVA, MPS IVA) is one of the 11 mucopolysaccharidoses (MPSs), a heterogeneous group of inherited lysosomal storage disorders (LSDs) caused by deficiency in enzymes need to degrade glycosaminoglycans (GAGs). Morquio A is characterized by a decrease in N-ac...

Descripción completa

Detalles Bibliográficos
Autores principales:	Donida, Bruna, Marchetti, Desirèe P., Jacques, Carlos Eduardo Diaz, Ribas, Graziela, Deon, Marion, Manini, Paula, da Rosa, Helen Tais, Moura, Dinara Jaqueline, Saffi, Jenifer, Giugliani, Roberto, Vargas, Carmen Regla
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5408501/ https://www.ncbi.nlm.nih.gov/pubmed/28487826 http://dx.doi.org/10.1016/j.ymgmr.2017.04.005

Ejemplares similares

Diagnosing mucopolysaccharidosis IVA
por: Wood, Timothy C., et al.
Publicado: (2013)

Role of elosulfase alfa in mucopolysaccharidosis IVA
por: Regier, Debra S, et al.
Publicado: (2016)

Atypical presentation of mucopolysaccharidosis type IVA
por: Rush, Eric T.
Publicado: (2016)

Mucopolysaccharidosis IVA: Diagnosis, Treatment, and Management
por: Sawamoto, Kazuki, et al.
Publicado: (2020)

Cochlear implantation in a patient with mucopolysaccharidosis IVA
por: Nagao, Kyoko, et al.
Publicado: (2019)

Pathophysiology of Hip Disorders in Patients with Mucopolysaccharidosis IVA
por: Wang, Zhigang, et al.
Publicado: (2020)

Bone Growth Induction in Mucopolysaccharidosis IVA Mouse
por: Rintz, Estera, et al.
Publicado: (2023)

Mucopolysaccharidosis IVA: Current Disease Models and Drawbacks
por: Leal, Andrés Felipe, et al.
Publicado: (2023)

The natural triterpene 3β,6β,16β-trihydroxy-lup-20(29)-ene obtained from the flowers of Combretum leprosum induces apoptosis in MCF-7 breast cancer cells
por: Viau, Cassiana Macagnan, et al.
Publicado: (2014)

Efeito Cardioprotetor da Suplementação Materna com Resveratrol sobre a Toxicidade Induzida por Doxorrubicina em Cardiomiócitos de Neonatos
por: Brito, Verônica Bidinotto, et al.
Publicado: (2021)

Natural history and clinical assessment of Taiwanese patients with mucopolysaccharidosis IVA
por: Lin, Hsiang-Yu, et al.
Publicado: (2014)

Clinical, radiologic, and genetic features of Korean patients with Mucopolysaccharidosis IVA
por: Lee, Na Hee, et al.
Publicado: (2012)

Determination of genotypic and clinical characteristics of Colombian patients with mucopolysaccharidosis IVA
por: Tapiero-Rodriguez, Sandra M, et al.
Publicado: (2018)

Characterization of New Proteomic Biomarker Candidates in Mucopolysaccharidosis Type IVA
por: Álvarez, Víctor J., et al.
Publicado: (2020)

Mucopolysaccharidosis Type IVA: Extracellular Matrix Biomarkers in Cardiovascular Disease
por: Montavon, Brittany, et al.
Publicado: (2022)

Endoscopic and Image Analysis of the Airway in Patients with Mucopolysaccharidosis Type IVA
por: Lee, Yi-Hao, et al.
Publicado: (2023)

Structural Aspects of Antioxidant and Genotoxic Activities of Two Flavonoids Obtained from Ethanolic Extract of Combretum leprosum
por: Viau, Cassiana Macagnan, et al.
Publicado: (2016)

Erratum: Clinical, radiologic, and genetic features of Korean patients with Mucopolysaccharidosis IVA
por: Lee, Na Hee, et al.
Publicado: (2013)

Muskoskeletal manifestations of mild form of mucopolysaccharidosis iva - a clinical case
por: Ganeva, Margarita, et al.
Publicado: (2014)

Development of Substrate Degradation Enzyme Therapy for Mucopolysaccharidosis IVA Murine Model
por: Sawamoto, Kazuki, et al.
Publicado: (2019)

Activity of daily living in mucopolysaccharidosis IVA patients: Evaluation of therapeutic efficacy
por: Chen, Hui, et al.
Publicado: (2021)

Clinical overview and treatment options for non-skeletal manifestations of mucopolysaccharidosis type IVA
por: Hendriksz, Christian J., et al.
Publicado: (2012)

Heart and Cardiovascular Involvement in Patients with Mucopolysaccharidosis Type IVA (Morquio-A Syndrome)
por: Kampmann, Christoph, et al.
Publicado: (2016)

Cardiac features and effects of enzyme replacement therapy in Taiwanese patients with Mucopolysaccharidosis IVA
por: Lin, Hsiang-Yu, et al.
Publicado: (2018)

Chondroitin sulfate disaccharide is a specific and sensitive biomarker for mucopolysaccharidosis type IVA
por: Chin, Sharon J., et al.
Publicado: (2020)

Respiratory Dysfunction in Children and Adolescents with Mucopolysaccharidosis Types I, II, IVA, and VI
por: Tulebayeva, Assel, et al.
Publicado: (2020)

Enhanced Efficiency of the Basal and Induced Apoptosis Process in Mucopolysaccharidosis IVA and IVB Human Fibroblasts
por: Brokowska, Joanna, et al.
Publicado: (2023)

Molecular basis of mucopolysaccharidosis IVA (Morquio A syndrome): A review and classification of GALNS gene variants and reporting of 68 novel variants
por: Zanetti, Alessandra, et al.
Publicado: (2021)

Spinal involvement in mucopolysaccharidosis IVA (Morquio-Brailsford or Morquio A syndrome): presentation, diagnosis and management
por: Solanki, Guirish A., et al.
Publicado: (2013)

Long-term therapeutic efficacy of allogenic bone marrow transplantation in a patient with mucopolysaccharidosis IVA()
por: Chinen, Yasutsugu, et al.
Publicado: (2014)

Corrections of diverse forms of lower limb deformities in patients with mucopolysaccharidosis type IVA (Morquio syndrome)
por: Al Kaissi, Ali, et al.
Publicado: (2016)

Diagnostic journey and impact of enzyme replacement therapy for mucopolysaccharidosis IVA: a sibling control study
por: Ficicioglu, Can, et al.
Publicado: (2020)

Elosulfase alfa in the treatment of mucopolysaccharidosis type IVA: insights from the first managed access agreement
por: Stevens, Bob, et al.
Publicado: (2021)

Clinical features and health-related quality of life in adult patients with mucopolysaccharidosis IVA: the Spanish experience
por: Quijada-Fraile, Pilar, et al.
Publicado: (2021)

Treatment of skeletal and non-skeletal alterations of Mucopolysaccharidosis type IVA by AAV-mediated gene therapy
por: Bertolin, Joan, et al.
Publicado: (2021)

Consensus statement on enzyme replacement therapy for mucopolysaccharidosis IVA in Central and South-Eastern European countries
por: Magner, Martin, et al.
Publicado: (2022)

Efficacy of Intravenous Elosulfase Alfa for Mucopolysaccharidosis Type IVA: A Systematic Review and Meta-Analysis
por: Lee, Chung-Lin, et al.
Publicado: (2022)

Mucopolysaccharidosis IVA (Morquio A syndrome) and VI (Maroteaux–Lamy syndrome): under-recognized and challenging to diagnose
por: Lachman, Ralph S., et al.
Publicado: (2014)

Clinical and molecular characteristics of colombian patients with mucopolysaccharidosis IVA, and description of a new galns gene mutation
por: Moreno Giraldo, Lina Johanna, et al.
Publicado: (2018)

Analysis of endocrine hormone metabolism level in a Chinese patient with mucopolysaccharidosis IVA: A case report
por: Xu, Linxin, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_j4dt5aq2kh955ia8ikvse554tt